-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dinutuximab Beta in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dinutuximab Beta in Neuroblastoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dinutuximab Beta in Neuroblastoma Drug Details: Dinutuximab beta (APN-311, Isqette, Qarziba)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dinutuximab Beta in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dinutuximab Beta in Neuroblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dinutuximab Beta in Neuroblastoma Drug Details: Dinutuximab beta (APN-311, Isqette, Qarziba) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – APN-01 in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APN-01 in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. APN-01 in Pulmonary Arterial Hypertension Drug Details: APN-01 is under development...
-
Product Insights
NewPulmonary Arterial Hypertension – Drugs In Development, 2024
Empower your strategies with our Pulmonary Arterial Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea, and other diseases, including congenital heart disease,...
-
Product Insights
NewRespiratory Distress Syndrome – Drugs In Development, 2024
Empower your strategies with our Respiratory Distress Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Respiratory distress syndrome (RDS) occurs in babies born early (premature) whose lungs are not fully developed. The earlier the infant is born, the more likely it is for them to have RDS and need extra oxygen and help breathing. It primarily affects premature infants due to insufficient surfactant, a lung-stabilizing substance. Without surfactant, the lungs collapse, causing breathing difficulties. Common in...
-
Product Insights
NewAcute Respiratory Distress Syndrome – Drugs In Development, 2024
Empower your strategies with our Acute Respiratory Distress Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia, and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure, confusion,...
-
Product Insights
NewPulmonary Hypertension – Drugs In Development, 2024
Empower your strategies with our Pulmonary Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary hypertension (PH) is a rare condition marked by high blood pressure in the pulmonary arteries, which supply blood to the lungs. It can stem from various causes, including heart or lung diseases. PH leads to arterial narrowing, forcing the heart to work harder, potentially resulting in heart failure. Common symptoms include breathlessness, fatigue, chest pain, and dizziness. Management involves medication, oxygen...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HTL-0039732 in Cervical Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Cervical Cancer Drug Details: HTL-0039732 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dinutuximab Beta in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dinutuximab Beta in Leiomyosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Dinutuximab Beta in Leiomyosarcoma Drug Details:Dinutuximab beta (APN-311, Isqette, Qarziba) is a chimeric...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – K-161 in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - K-161 in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using...